Skip to content
You are now leaving to visit

Phase 1b/2 Data of Durvalumab Plus Danvatirsen Presented at European Society for Medical Oncology

Response rate approximately doubled compared to previous studies with durvalumab alone in refractory head and neck cancer Danvatirsen, Ionis’ most advanced Generation 2.5 antisense drug, demonstrated potential to treat intractable cancers CARLSBAD, Calif. , Oct.